Benefit of transfusion-related acute lung injury risk-minimization measures--German haemovigilance data (2006-2010).
about
Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical useAdverse effects of plasma transfusionLow-risk transfusion-related acute lung injury donor strategies and the impact on the onset of transfusion-related acute lung injury: a meta-analysis.Antibody-mediated transfusion-related acute lung injury; from discovery to prevention.Transfusion-related acute lung injury: transfusion, platelets and biological response modifiers.Comparing transfusion reaction rates for various plasma types: a systematic review and meta-analysis/regression.Independent evaluation of tolerance of therapeutic plasma inactivated by amotosalen-HCl-UVA (Intercept ™) over a 5-year period of extensive delivery.A regional haemovigilance retrospective study of four types of therapeutic plasma in a ten-year survey period in France.Transfusion reactions: a comparative observational study of blood components produced before and after implementation of semiautomated production from whole blood.[Transfusion-related acute lung injury].Transfusion-related acute lung injury risk mitigation: an update.Predicted effect of selectively testing female donors for HLA antibodies to mitigate transfusion-related acute lung injury risk from apheresis platelets.Residual plasma in red blood cells and transfusion-related acute lung injury.Anti-leucocyte antibodies in platelet apheresis donors with and without prior immunizing events: implications for TRALI prevention.The residual risk of transfusion-related acute lung injury at the American Red Cross (2008-2011): limitations of a predominantly male-donor plasma mitigation strategy.The prevalence of leucocyte alloantibodies in blood donors from South China.Two cases of maternal alloimmunization against human neutrophil alloantigen-4b, one causing severe alloimmune neonatal neutropenia.
P2860
Q26741073-416A1807-713E-4D08-BCE0-51FB4C388F78Q35972184-2F36EAE6-8810-460C-A129-5A4718A98EF4Q38241123-38A4F7DC-2B77-4B65-B6CB-4C36B9568495Q38447155-504D6FA2-C1DF-4F74-9333-D99543CD43B1Q38725992-479CC560-94BC-4E65-9801-FF85E54AEBECQ40098378-BB340D0F-FA29-4D1E-9328-178E27757719Q40882231-C5425A99-5BB4-47DE-BB7C-89F9E9E17F0DQ43779317-54696679-44F4-4250-9899-676649E030F7Q44219668-F9342E42-6218-4BBA-BD23-7855A6BE583DQ45058712-24521AA0-1260-4548-B275-91780FB72606Q47628286-E1FF6459-8E30-49C3-A5A2-BF2DFA1C6F77Q50264305-774ADCA7-0E38-4C6A-871D-1B6799EB3095Q50473056-AC2CC8C6-5D4C-480E-9319-46FA948A2385Q50489643-223CDC77-1D3C-474B-B7EC-F58C01E6004CQ50501123-67A47D7F-FE6C-4B13-AE0B-BD8EC97DDC4FQ50931060-D4572F56-B9AE-4580-ADB2-8E56E190D0AFQ50989287-01345F33-1B4A-4884-8CAD-5EE95DB44FBD
P2860
Benefit of transfusion-related acute lung injury risk-minimization measures--German haemovigilance data (2006-2010).
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Benefit of transfusion-related ...... emovigilance data (2006-2010).
@ast
Benefit of transfusion-related ...... emovigilance data (2006-2010).
@en
Benefit of transfusion-related ...... es--German haemovigilance data
@nl
type
label
Benefit of transfusion-related ...... emovigilance data (2006-2010).
@ast
Benefit of transfusion-related ...... emovigilance data (2006-2010).
@en
Benefit of transfusion-related ...... es--German haemovigilance data
@nl
prefLabel
Benefit of transfusion-related ...... emovigilance data (2006-2010).
@ast
Benefit of transfusion-related ...... emovigilance data (2006-2010).
@en
Benefit of transfusion-related ...... es--German haemovigilance data
@nl
P2093
P2860
P1433
P1476
Benefit of transfusion-related ...... emovigilance data (2006-2010).
@en
P2093
B Keller-Stanislawski
K M O Hanschmann
O Henseler
P2860
P304
P356
10.1111/J.1423-0410.2011.01556.X
P577
2011-10-04T00:00:00Z